Allergy Therapeutics keeps buy rating from Jefferies

Jefferies & Co., Inc. analyst Robin Campbell kept Allergy Therapeutics plc at a buy. The analyst believes the company is on the cusp of the "big time" with a growing Euro-sales franchise and a novel, high-potential commercial allergy vaccine, AGY. The delay of the PQ Tree is unfortunate, but Grass phase 3 and possibly ragweed, plus partnering are worth the investment. Shares of the Worthing, U.K.-based pharmaceutical company were up 2.53p, or 2.43%, at 106.63p. (London: AGY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.